Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis

European Respiratory Journal

Volumn 15, Issue 2, 2000, Pages 342-349

  Hidi, R ^a   Timmermans, S ^a   Liu, E ^a   Schudt, C ^b   Dent, G ^a   Holgate, S T ^a   Djukanovic R ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b ALTANA PHARMA AG   (Germany)

Author keywords

3',5' cyclic adenosine monophosphate; Chemotaxis; Cyclic nucleotide phosphodiesterase; Rolipram; T lymphocytes; Theophylline

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUCLADESINE; CYCLIC AMP; FORSKOLIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE;

ARTICLE; ASTHMA; ATOPY; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ALBUTEROL; ASTHMA; BUCLADESINE; CHEMOTAXIS, LEUKOCYTE; CYCLIC AMP; FORSKOLIN; HUMANS; INTERLEUKIN-8; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PLATELET ACTIVATING FACTOR; ROLIPRAM; T-LYMPHOCYTES; THEOPHYLLINE;

EID: 0033952050     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.15b21.x     Document Type: Article

References (48)

1. Kay AB. Lymphocytes in asthma. Respir Med 1991; 85: 87-90.
2. Louis R, Shute J, Biagi S, et al. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. Am J Respir Crit Care Med 1997; 155: 466-472.
3. Djukanović R, Feather I, Gratziou C, et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996; 51: 575-581.
4. Metzger WJ, Zavala D, Richerson HB. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Am Rev Respir Dis 1987; 135: 433-440.
5. Ohashi Y, Motojima S, Fukuda T, Makino S. Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. Am J Respir Crit Care Med 1992; 145: 1469-1476.
6. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 1995; 151: 879-886.
7. Hidi R, Louis R, Holgate S, Djukanović R. Chemotactic activity for T-cells detected in sputa from atopic asthmatics. Am J Respir Crit Care Med 1997; 155: A542.
8. Hidi R, Riches V, Holgate ST, Djukanović R. Chemotactic activity for T-cells generated in an explant of biopsies from atopic asthmatic patients. Am J Respir Crit Care Med 1997; 155: A816.
9. Ward AJM, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline - an immunomodulatory role in asthma? Am Rev Respir Dis 1993; 147: 518-523.
10. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon γ) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12: 477-487.
11. Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. N Engl J Med 1973; 289: 600-603.
12. Kidney JC, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907-1914.
13. Djukanović R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J 1995; 8: 831-833.
14. Scordamaglia A, Ciprandi G, Ruffoni S, et al. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol 1988; 48: 238-246.
15. Limatibul S, Shore A, Dosch HM, Gelfand EW. Theophylline modulation of E-rosette formation: an indicator of T-cell maturation. Clin Exp Immunol 1978; 33: 503-513.
16. McFadden RG, Bishop MA, Cavcney AN, Fraher LJ. Effect of platelet activating factor (PAF) on the migration of human lymphocytes. Thorax 1995; 50: 265-269.
17. Barrett ML, Lewis GP, Ward S, Westwick J. Platelet-activating factor modulates interleukin-2 proliferation of human T-lymphoblasts. Br J Pharmacol 1986; 89: 505P.
18. Marini M, Vittori E, Hollemborg J, Mattoli S. Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. J Allergy Clin Immunol 1992; 89: 1001-1009.
19. Yousefi S, Hemmann S, Weber M, et al. IL-8 is expressed by human peripheral blood eosinophils: evidence for increased secretion in asthma. J Immunol 1995; 154: 5481-5490.
20. Konno S, Gonokami Y, Kurokawa M, et al. Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Immunol 1996; 109: 73-78.
21. Shute JK, Lindley I, Peichl P, Holgate ST, Church MK, Djukanovic R. Mucosal IgA is an important moderator of eosinophil responses to tissue-derived chemoattractants. Int Arch Allergy Immunol 1995; 107: 340-341.
22. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T-lymphocytes. Science 1989; 243: 1464-1466.
23. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150-155.
24. Soderling SH, Bayuga SJ, Beavo JA. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Nad Acad Sci USA 1998; 95: 8991-8996.
25. Fredholm BB. Theophylline actions on adenosine receptors. Eur J Respir Dis Suppl. 1980; 109: 29-36.
26. Poisner AM. Direct stimulant effect of aminophylline on catecholamine release from the adrenal medulla. Biochem Pharmacol 1973; 22: 469-476.
27. Verghese MW, McConnell RT, Strickland AB, et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995; 272: 1313-1320.
28. Tenor H, Staniciu L, Schudt C, et al. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T-lymphocytes. Clin Exp Allergy 1995; 25: 616-624.
29. Giembycz MA, Corrigan CJ, Scybold J, Newton R. Barnes PJ. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996; 118: 1945-1958.
30. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel anti-asthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
31. Stanciu LA, Shute J, Holgate ST, Djukanović R. Production of IL-8 and IL-4 by positively and negatively selected CD4+ and CD8+ human T-cells following a four-step cell separation method including magnetic cell sorting (MACS). J Immunol Methods 1996; 189: 107-115.
32. Wilson JW, Djukanovic R, Howarth PH, Holgate ST. Lymphocyte activation in bronchoalveolar lavage and peripheral blood in atopic asthma. Am Rev Respir Dis 1992; 145: 958-960.
33. Kravchenko W, Pan Z, Han J, Herbert JM, Ulevitch RJ, Ye RD. Platelet-activating factor induces NF-κB activation through a G protein-coupled pathway. J Biol Chem 1995; 270: 14928-14934.
34. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994; 12: 593-633.
35. Williams KA, Haslam RJ. Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor). Biochim Biophys Acta 1984; 770: 216-223.
36. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995; 25: 147-153.
37. Ukena D, Schudt C, Sybrecht GW. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes. Biochem Pharmacol 1993; 45; 847-851.
38. Barankiewicz J, Ronlov G, Jimenez R, Gruber HE. Selective adenosine release from human B but not T-lymphoid cell line. J Biol Chem 1990; 265: 15738-15743.
39. Nielson CP, Crowley JJ, Morgan ME, Vestal RE. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3′,5′-adenosine monophosphate. Am Rev Respir Dis 1988; 137: 25-30.
40. Bacon KB, Westwick J, Camp RD. Potent and specific inhibition of IL-8-, IL-Iα- and IL-1β induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 1989; 165: 349-354.
41. Cruikshank WW, Center DM, Nisar N, et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994; 91: 5109-5113.
42. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T-lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671.
43. Loctscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T-lymphocytes. FASEB J 1994; 8: 1055-1060.
44. Tanaka J, Nomiyama H, Yamamoto T, Hamada F, Kambara T. T-cell chemotactic activity of cytokine LD78: a comparative study with interleukin-8, a chemotactic factor for the T-cell CD45RA+ phenotype. Int Arch Allergy Immunol 1993; 100: 201-208.
45. Akbar AN, Terry L, Timms A, Beverley PC, Janossy G. Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T-cells. J Immunol 1988; 140: 2171-2178.
46. Newman I, Wilkinson PC. Locomotor responses of human CD45 lymphocyte subsets: preferential locomotion of CD45RO+ lymphocytes in response to attractants and mitogens. Immunology 1993; 78: 92-98.
47. Lacour M, Arrighi JF, Muller KM, Carlberg C, Saurat JH, Hauser C. cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T-cells while decreasing IL-2 release and NF-AT induction. Intern Immunol 1994; 6: 1333-1343.
48. Garrido E, Delgado M, Martinez C, Gomariz RP, De la Fuente M. Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility. Neuropeptides 1996; 30: 583-595.